Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00136903 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)
A Phase 2 study of Graft Vs Host Disease, sponsored by Mesoblast.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 9
- Study locations
NCT00136903: Completed Phase 2 study of Graft Vs Host Disease, sponsored by Mesoblast.
NCT00136903 is a Phase 2 study of Graft Vs Host Disease that has completed, run by Mesoblast. The registered enrollment target is 32 participants, below the 137-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (77% lower). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00136903, a Phase 2 study of Graft Vs Host Disease, has completed, sponsored by Mesoblast.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 9
- Study locations
Study Summary
To establish the safety and efficacy of two dose levels of ex-vivo cultured adult human mesenchymal stem cells (hMSCs) (Prochymal®) in participants experiencing acute GVHD, Grades II-IV, post hematopoietic stem cells (HSC) transplant.
Conditions Studied
Interventions
- DRUG Prednisone
- DRUG Methylprednisolone
- DRUG Cyclosporine
- DRUG Prochymal® - 2 Million cells/kg
- DRUG Prochymal®- 8 Million cells/kg
Study Locations (9)
New York
- Roswell Park Cancer Institute - Buffalo
- Mt. Sinai Hospital - New York
- University of Rochester - Rochester
- New York Medical College - Valhalla
Indiana
- St. Francis Hospital - Indianapolis
Missouri
- Kansas City Cancer Centers - BMT - Kansas City
New Jersey
- The Cancer Center at Hackensack University - Hackensack
Texas
- MD Anderson Cancer Center - Houston
Wisconsin
- Medical College of Wisconsin, FEC - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2005-04-27 |
| Est. Completion | 2008-07-14 |
| Phase | Phase 2 |
What the finished NCT00136903 record still lists
NCT00136903 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 137-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Graft Vs Host Disease appearing as the primary indexed condition, and to 5 interventions - of which Prednisone is the first listed.
NCT00136903 lists 9 locations in 6 states (New York, Indiana, Missouri).
Frequently Asked Questions
What is clinical trial NCT00136903 about?
NCT00136903 is a clinical study titled "Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)". To establish the safety and efficacy of two dose levels of ex-vivo cultured adult human mesenchymal stem cells (hMSCs) (Prochymal®) in participants experiencing acute GVHD, Grades II-IV, post hematopoietic stem cells (HSC) transplant.
What is the current status of trial NCT00136903?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2005-04-27. Estimated completion is 2008-07-14.
What conditions does trial NCT00136903 study?
This clinical trial studies the following conditions: Graft Vs Host Disease.
What interventions are being tested in trial NCT00136903?
The interventions under investigation include: Prednisone (DRUG), Methylprednisolone (DRUG), Cyclosporine (DRUG), Prochymal® - 2 Million cells/kg (DRUG), Prochymal®- 8 Million cells/kg (DRUG).
Who is sponsoring clinical trial NCT00136903?
This trial is sponsored by Mesoblast, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00136903 being conducted?
This trial has 9 study locations across Indiana, Missouri, New Jersey, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft Vs Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00136903's enrollment target sits among peer trials
32 27th of 36 higher than 10 of 36 other Graft Vs Host Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Graft Vs Host Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis
RECRUITING · Phase 2
-
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
RECRUITING · Phase 2
-
Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.
RECRUITING · Phase 2
-
Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD
ACTIVE NOT RECRUITING · Phase 2
-
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
ACTIVE NOT RECRUITING · Phase 2
-
RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI